Mobile Apps for ADHD

Recruiting at 1 trial location

Overseen By Stephen P Hinshaw, Ph.D.

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Think Now Incorporated

Must not be taking: Antipsychotics, Benzodiazepines, Anticonvulsants, others

Disqualifiers: Bipolar, Psychotic, PTSD, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

Duration: 7 weeks

140 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing smartphone apps designed to help adults with ADHD. The apps aim to improve attention and other mental skills through brain-training exercises. Participants will use the apps at home for several weeks, with assessments conducted at different stages of the treatment period.

Will I have to stop taking my current medications?

The trial requires stopping certain medications that affect attention, such as guanfacine, Strattera, Modafinil, Armodafinil, and Clonidine, due to the need for a long washout period (time without taking these medications). If you are on other medications that affect attention, you may need to stop them if they are on the Excluded Medications List.

What data supports the effectiveness of the treatment UC-A, UC-N for ADHD?

Research shows that mobile apps and computer-based programs can be promising tools for delivering ADHD treatments, such as cognitive-behavioral therapy (CBT), which has shown effectiveness in managing ADHD symptoms. Additionally, mobile health apps have been found to increase treatment adherence and improve knowledge about ADHD. ^{1 2 3 4 5}

How does the treatment UC-A, UC-N differ from other ADHD treatments?

The treatment UC-A, UC-N is unique because it involves the use of mobile apps, which may offer a more accessible and flexible approach compared to traditional ADHD treatments that often rely on medication or in-person therapy sessions. ^{6 7 8 9 10}

Research Team

Robert Bilder, Ph.D

Principal Investigator

University of California, Los Angeles

Eligibility Criteria

This trial is for adults who have been diagnosed with ADHD. The specific eligibility criteria are not provided, so it's important to contact the study organizers for detailed information on who can participate.

Inclusion Criteria

Have a smart Phone

Estimated Intelligence Quotient (IQ) > 80 as assessed by the Wechsler Abbreviated Scale Intelligence (WASI-II) Matrix Reasoning and Vocabulary subtests

Meet established Diagnostic and Statistical Manual of Mental Health-Fifth Edition (DSM-5-TR) presentation for ADHD predominantly inattentive or combined subtype with clinically significant levels of impairment, diagnosed by semi-structured clinical interview and the Adult ADHD Clinical Diagnostic Scale (ACDS)

Exclusion Criteria

Lifetime history of DSM5 bipolar disorder, psychotic disorder, panic disorder, agoraphobia, obsessive compulsive disorder as assessed with the MINI International Neuropsychiatric Interview (MINI)

History of diagnosis of childhood neurodevelopmental disorder including autism spectrum disorder and dyslexia, other than ADHD or those specifically allowed in the Allowed Disorders section

Substance or Alcohol Use Disorder rated as moderate or severe, with symptoms ≥ 4, as assessed by the MINI, or self-report of a Substance/Alcohol Use Disorder (allow endorsement of substance or alcohol use that does not meet moderate-severe use disorder criterion, if clean at visit)

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Baseline

Pre-treatment assessments conducted on-site

1 day

1 visit (in-person)

Treatment

Participants use the digital therapy at home

7 weeks

1 visit (in-person) at midpoint, 1 visit (in-person) at endpoint

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• UC-A
• UC-N

Trial Overview The trial is testing two mobile app digital therapies, referred to as UC-A and UC-N, to see how they affect cognitive function and symptoms in adults with ADHD.

Participant Groups

Group I: UC-A Active Control 1 Intervention

UC-0A is a digital mobile app intervention that uses cognitive control skills for task performance. The intervention is used once a day, 5 days a week, for 7 weeks.

Group II: UC-N Active Control 1 Intervention

UC-0N is a digital mobile app intervention that uses cog control skills for problem solving. The intervention is used once a day, 5 days a week, for 7 weeks.

Who Is Running the Clinical Trial?

Think Now Incorporated

Lead Sponsor

Trials

4

Recruited

590+

University of California, Los Angeles

Collaborator

Trials

1,594

Recruited

10,430,000+

University of California, Berkeley

Collaborator

Trials

193

Recruited

716,000+

Findings from Research

Several new therapies for gout have emerged, focusing on lowering serum urate levels and treating gout flares, with verinurad being highlighted as the most promising urate-lowering therapy.

Arhalofenate shows potential for both urate lowering and anti-inflammatory effects, but further data is needed to confirm its efficacy and safety, along with other therapies like bucillamine and those in early development.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Expert opinion on emerging urate-lowering therapies. Stamp, LK., Merriman, TR., Singh, JA.[2018]

References

1. England pubmed.ncbi.nlm.nih.gov

Evaluation of the effectiveness of the FOCUS ADHD App in monitoring adults with attention-deficit/hyperactivity disorder. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Usability and feasibility of a cognitive-behavioral mobile app for ADHD in adults. [2023]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Perspectives on caregiver-focused MHealth Technologies to improve mental health treatment for low-income youth with ADHD. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Personalized Remote Mobile Surveys of Adult ADHD Symptoms and Function: A Pilot Study of Usability and Utility for Pharmacology Monitoring. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Acceptability and playability of an organization training videogame for young adolescents with ADHD: The development of ATHEMOS. [2023]

6. England pubmed.ncbi.nlm.nih.gov

Current and future therapies for gout. [2018]

7. United Arab Emirates pubmed.ncbi.nlm.nih.gov

The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders. [2022]

8. Switzerland pubmed.ncbi.nlm.nih.gov

Potential of Ascorbic Acid Supplements to Ameliorate the Deleterious Effects of Hyperuricemia on Albino Wistar Rats' Hippocampus (Structural and Functional Study). [2023]

9. England pubmed.ncbi.nlm.nih.gov

Expert opinion on emerging urate-lowering therapies. [2018]

10. United States pubmed.ncbi.nlm.nih.gov

Progress in the pharmacotherapy of gout. [2017]